MedTrace Logo

Safety, Pharmacokinetics and Clinical Activity of AZD0171 in Combination With Durvalumab and Chemotherapy in Locally Advanced or Metastatic Solid Tumours

NCT04999969 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 126

Last updated 2026-04-30

Study results available
· View outcomes & findings →

Summary

The proposed study is designed to examine the effects of AZD0171 and durvalumab in combination with standard-of-care chemotherapy in patients with pancreatic ductal adenocarcinoma (PDAC).

Conditions

  • Locally Advanced or Metastatic Solid Tumours

Interventions

DRUG

AZD0171

AZD0171

DRUG

Durvalumab

Durvalumab

DRUG

Gemcitabine

Chemotherapy (Standard-of-Care)

DRUG

Nab-paclitaxel

Chemotherapy (Standard-of-Care)

Sponsors & Collaborators

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
130 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-12-10
Primary Completion
2024-10-07
Completion
2026-06-30
FDA Drug
Yes

Countries

  • United States
  • Canada
  • South Korea
  • Spain

Study Locations

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04999969 on ClinicalTrials.gov